OncoMatch/Clinical Trials/NCT05654454
A Safety and Efficacy Study of Bevacizumab, Paclitaxel, Carboplatin Compared to Avastin® in Non-Small Cell Lung Cancer
Is NCT05654454 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Bevacizumab and Paclitaxel for non-small cell lung cancer.
Treatment: Bevacizumab · Paclitaxel · Carboplatin — BEV-III/2022 is a double-blind randomized multicenter clinical trial comparing efficacy of bevacizumab (manufactured by Mabscale, LLC) and paclitaxel plus carboplatin to Avastin® and paclitaxel plus carboplatin in first-line treatment for patients with advanced (unresectable, locally advanced, recurrent or metastatic) non-squamous NSCLC. The purpose of the study is to demonstrate equivalence of efficacy and safety of bevacizumab (manufactured by Mabscale, LLC) to Avastin®. Study includes pharmacokinetics assessment.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Excluded: ALK fusion
Excluded: EGFR sensitizing mutation
Disease stage
Required: Stage IIIB, IIIC, IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Lab requirements
Blood counts
Neutrophils ≥ 1.5 × 10^9/L; Platelets ≥ 100 × 10^9/L; Haemoglobin ≥ 90 g/L
Liver function
Bilirubin level ≤ 1.5 × ULN; AST and ALT < 3 × ULN (< 5 × ULN for patients with liver metastases); Alkaline phosphatase level < 3 × ULN (< 5 × ULN for patients with liver or bone metastases)
Neutrophils ≥ 1,5 × 10^9/L; Platelets ≥ 100 × 10^9/L; Haemoglobin ≥ 90 g/L; Bilirubin level ≤ 1.5 × ULN; AST and ALT < 3 × ULN (< 5 × ULN for patients with liver metastases); Alkaline phosphatase level < 3 × ULN (< 5 × ULN for patients with liver or bone metastases)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify